USFDA issues EIR for Granules Indias Gagillapur plant
New Delhi: Drug firm Granules India on Wednesday said the US health regulator has issued establishment inspection report for its Gagillapur plant in Hyderabad without any observations.
The United States Food and Drug Administration (USFDA) has issued establishment inspection report (EIR) for the company's Gagillapur facility in Hyderabad, Granules India said in a regulatory filing.
"The facility was inspected by the USFDA in October 2016 and there were no observations during the inspection", it added.
Finished dosages and pharmaceutical formulation intermediates are manufactured at the plant, it said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd